Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
August 19, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
August 19, 2002
- AMO Japan Sees Split from Allergan as a Major Advantage: President Akedo
August 19, 2002
- OTC NEWS IN BRIEF
August 19, 2002
- Taisho, Toyama Agree to Form Capital, Business Alliance
August 19, 2002
- NEW PRODUCTS
August 19, 2002
- Olympus to Raise Sales to \870 Bil. in 5 Years
August 19, 2002
- MEETING
August 19, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
August 19, 2002
- MEDICAL DEVICE NEWS IN BRIEF
August 19, 2002
- To Further Concentrate on Ethical Drug Business: Takeda President
August 19, 2002
- FY2000 Nat'l Medical Costs Down 1.9% Due to Nursing Care Insurance
August 19, 2002
- DIAGNOSTIC NEWS IN BRIEF
August 19, 2002
- Kyowa Hakko to Start SMART Marketing Strategy in October
August 19, 2002
- Korosho Official Briefs on "General Manufacturing and Marketing Managers"
August 19, 2002
- WORLD NEW IN BRIEF
August 19, 2002
- Nikken to Transfer Chemical Business to Mitsui
August 19, 2002
- PFSB Negotiates Hike of Review Fees with Industry
August 19, 2002
- Daiichi, Suntory Hope for \20-30 Bil. Sales for New Company
August 19, 2002
- MCC to Review Disadvantages of Split-off Policy
August 19, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…